Mi-RNA and COVID-19
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Mar 15, 2025
Trial Information
Current as of May 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Mi-RNA and COVID-19," is focused on understanding how certain molecules in our bodies, known as microRNAs (miRNAs), are connected to COVID-19 infections. Researchers want to learn how these miRNAs might relate to the severity of the illness and the risk of dying from it. COVID-19 can cause a range of problems, from mild symptoms to severe respiratory issues that may require hospitalization. By studying these miRNAs, the trial hopes to find better ways to predict and treat COVID-19.
To join this study, participants need to be at least 18 years old and must have a confirmed diagnosis of a COVID-19 infection through a specific test. However, pregnant women are not eligible to participate. If you decide to take part, you can expect to provide samples for testing and contribute to important research that could help improve care for others with COVID-19. This trial is currently recruiting participants, so it’s a chance to make a difference in the fight against this disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years
- • diagnosis of SARS-CoV-2 infection confirmed by molecular testing on nasopharyngeal swabs
- Exclusion Criteria:
- • pregnant women
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, Rm, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported